The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).
A new social media campaign called #ThinkHand aims to challenge perceptions about what is important for multiple sclerosis patients - and also bring about changes in drug trials.
